<SEC-DOCUMENT>0001140361-21-020543.txt : 20210610
<SEC-HEADER>0001140361-21-020543.hdr.sgml : 20210610
<ACCEPTANCE-DATETIME>20210610172037
ACCESSION NUMBER:		0001140361-21-020543
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210605
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210610
DATE AS OF CHANGE:		20210610

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		211009005

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10025686_8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 8-K</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CURRENT REPORT</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Date of Report (Date of earliest event reported): <font style="font-weight: bold;">June 5, 2021</font></div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z7fdcad37e62c4e32ac2fec3c65d77ff8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">001-11460</div>
            </td>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">31-1103425</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Commission File Number)</div>
            </td>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(IRS Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z8db95e0eaac842b99de01fab7ad6d444" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">140 58<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, Building A, Suite 2100</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn, New York</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">11220</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Registrant&#8217;s telephone number, including area code: <font style="font-weight: bold;">(212) 582-1199</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd695b357ad5748959e0ab8b882799d22" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
            <td style="width: auto; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z2d5689e786b14ada880422562047f06b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
            <td style="width: auto; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb5739afee1834d958a6529c093c5c394" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
            <td style="width: auto; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z3e8bccb207c94ce1aa7bebaedb80e5eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z319ebf94da384cd395bc4e0b40daea6d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 46.16%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of each class</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading symbol</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 31.84%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of each exchange on which registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 46.16%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Common Stock, par value $0.005 per share<br>
              </div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 18%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">BTX</div>
            </td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 31.84%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">NYSE American</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:</div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: right; color: rgb(0, 0, 0);">Emerging growth company&#160; &#9744;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
        provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</div>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze414b8b8c3714149885a24e2c0474434" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; font-weight: bold;">Item 5.02.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;">On June 8, 2021, we announced that Kevin A. D&#8217;Amour, Ph.D., had been appointed as our Chief Scientific Officer, effective June 28, 2021.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-style: italic; font-weight: bold;">Employment Agreement with Kevin A. D&#8217;Amour</div>
      <div>&#160;</div>
      <div style="text-align: justify;">We entered into an employment agreement, dated June 5, 2021 and effective as of June 28, 2021, with Kevin A. D&#8217;Amour with respect to terms of his employment as our Chief Scientific Officer. The compensatory terms of
        the employment agreement, including equity awards, were approved by the compensation committee of the board of directors, which consists of two disinterested members of the board. Dr. D&#8217;Amour&#8217;s hiring, and his employment agreement, were approved by
        the board.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">The employment agreement provides for our at-will employment of Dr. D&#8217;Amour as our Chief Scientific Officer for a term commencing on June 28, 2021 and continuing until terminated by us or Dr. D&#8217;Amour.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Under the terms of the employment agreement, we will pay Dr. D&#8217;Amour an annual base salary of $415,000, which amount is subject to annual review by the board or the compensation committee and subject to adjustment to
        reflect market practices among our peers in the sole discretion of the board or the compensation committee.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Dr. D&#8217;Amour will be eligible to receive an annual cash bonus award in an amount up to 40% of his base salary upon achievement of reasonable performance targets set by the board or the compensation committee, each in
        its sole discretion. The bonus will be determined by the board or the compensation committee and paid annually in March in the year following the performance year on which such bonus is based.</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0);">In accordance with the terms of the employment agreement, we will grant to Dr. D&#8217;Amour, effective as of June 28, 2021, a time-based nonqualified stock option, which we refer to as the Option
          Grant, and a time-based restricted stock unit grant, which we refer to as the RSU Grant. The Option Grant and the RSU Grant together will have a grant date fair value for accounting purposes of $5,763,000, or the Grant Value, which will be
          apportioned equally between the Option Grant and the RSU Grant using a 30-day volume-weighted average stock price as of the grant date and a conversion factor of a stock option award covering two shares to a restricted stock unit award covering
          one share.</div>
        <div>&#160;</div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z31224af5a18e41c098b0b19d7ab17d87" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">The Option Grant will cover a number of shares of common stock equal to one-half of the Grant Value, <font style="font-style: italic;">provided</font> that the number of shares covered by the Option Grant
                  shall not be less than 115,020 or greater than 140,580. The Option shall have an exercise price equal to the closing price of the common stock on the grant date.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z39c631c8024646439d36c5d8ee2331fa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">The RSU Grant will cover a number of shares of common stock equal to one-half of the Grant Value, <font style="font-style: italic;">provided</font> that the number of shares covered by the RSU Grant shall
                  not be less than 57,510 or greater than 70,290.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The Option Grant and the RSU Grant each will vest over four years, with vesting generally subject to Dr. D&#8217;Amour&#8217;s continued employment through the relevant vesting date. </font>Consistent



          with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, the equity award to Dr. D&#8217;Amour was made <font style="color: rgb(0, 0, 0);">as an inducement material to his entering into employment
            with us and was approved by the compensation committee without need for stockholder approval.</font></div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0);">If Dr. D&#8217;Amour&#8217;s employment is terminated by us without Cause or by Dr. D&#8217;Amour for Good Reason (each such capitalized term as defined in the employment agreement), he will be entitled to,
          among other things, continued base salary for nine months following the termination date and the total monthly cost of health care continuation coverage pursuant to COBRA for such period. Notwithstanding the foregoing, if a termination without
          Cause or for Good Reason occurs within ninety days before or twelve months after a Change in Control (as defined in the employment agreement), Dr. D&#8217;Amour would become entitled to (a) receive the continued-based salary and total monthly cost of
          health care continuation coverage described in the preceding sentence for a period of twelve months rather than nine months, (b) receive a lump sum payment of his target annual bonus and (c) accelerated vesting in full of the Option Grant and the
          RSU Grant. Any of such severance benefits under the employment agreement are contingent on Dr. D&#8217;Amour entering into and not revoking a general release of claims in favor of our company.</div>
        <div>&#160;</div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0);">The employment agreement provides for (a) reimbursement of reasonable business expenses, (b) participation in our benefit plans and (c) twenty paid vacation days per year.</div>
        <div>&#160;</div>
        <div style="text-align: justify; color: rgb(0, 0, 0);">The employment agreement contains customary covenants related to non-competition and non-solicitation for one year following termination of employment, as well as customary covenants related to
          confidentiality, inventions and intellectual property rights.</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">The foregoing description of Dr. D&#8217;Amour&#8217;s employment agreement with us does not purport to be complete and is subject to, and qualified in its entirety by, the full text of
        the agreement, which is included as Exhibit 10.1 to this report and is incorporated into this Item 5.02 by reference.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Background of Kevin A. D&#8217;Amour</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Kevin A. D&#8217;Amour, Ph.D, has served at ViaCyte, Inc., a clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, as Vice President, Research and Chief Scientific
        Officer since 2011. He served as Director, Stem Cell Biology of ViaCyte from 2010 to 2011 and as a Scientist, Senior Scientist and then Principal Scientist of ViaCyte from 2002 to 2010. Dr. D&#8217;Amour received a Ph.D. in Biology from the University of
        California, San Diego and a B.S. in Animal Science from the University of New Hampshire. He is 48 years old.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5e635f4f7f1c49d9a23d798cd1946a53" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; vertical-align: top; font-weight: bold;">Item 9.01.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z00e5ee31ca624953bbe8efcfc07e6dcb" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td nowrap="nowrap" style="width: 8.43%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Exhibit</div>
              <div style="text-align: justify; font-weight: bold;">Number</div>
            </td>
            <td style="width: 1.5%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td nowrap="nowrap" style="width: 90.08%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Exhibit Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.43%; vertical-align: top;">
              <div style="text-align: center;"><a href="brhc10025686_ex10-1.htm">10.1+*</a></div>
            </td>
            <td style="width: 1.5%; vertical-align: top;">&#160;</td>
            <td style="width: 90.08%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Executive Employment Agreement, dated as of June 5, 2021 and effective as of June 28, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Kevin A. D&#8217;Amour.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.43%; vertical-align: top;">
              <div style="text-align: center;"><a href="brhc10025686_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 1.5%; vertical-align: top;">&#160;</td>
            <td style="width: 90.08%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Press release of Brooklyn ImmunoTherapeutics, Inc. dated June 8, 2021.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z964e17aa9cc24ab4b3bc74415a0c577f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">+</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Indicates management contract or compensatory plan.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za00c9d5391924419b2382c39303d3bbc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">*</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">An addendum has been omitted pursuant to Item 601(a)(5) of Regulation S-K. We hereby undertake to furnish copies of the omitted addendum upon request by the Securities and Exchange Commission, provided that
                we may request confidential treatment pursuant to Rule 24b&#8209;2 of the Securities Exchange Act of 1934 for the addendum so furnished.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURE</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z50ee107083994bc4843002ab991f0714" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.96%; vertical-align: top;">&#160;</td>
            <td style="width: 50.04%; vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">&#160;</td>
            <td style="width: 50.04%; vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">&#160;Dated: June 10, 2021</div>
            </td>
            <td style="width: 3.09%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 46.96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Howard J. Federoff</td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">&#160;</td>
            <td style="width: 3.09%; vertical-align: top;">&#160;</td>
            <td style="width: 46.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.96%; vertical-align: top;">&#160;</td>
            <td style="width: 3.09%; vertical-align: top;">&#160;</td>
            <td style="width: 46.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10025686_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.1</font><br>
    </div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">EXECUTIVE EMPLOYMENT AGREEMENT</div>
      <div style="text-align: center; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This EXECUTIVE EMPLOYMENT AGREEMENT (this &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;) dated as of June 5, 2021, is entered by and between Brooklyn ImmunoTherapeutics,
        Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), and Kevin D&#8217;Amour, PhD (&#8220;<font style="font-weight: bold; font-style: italic;">Executive</font>&#8221;) and will be effective as of June 28, 2021
        (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;).&#160; Each of the Company and Executive are a &#8220;<font style="font-weight: bold; font-style: italic;">Party</font>,&#8221; and collectively, they are the &#8220;<font style="font-weight: bold; font-style: italic;">Parties</font>.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Company wishes to employ Executive as of the Effective Date; and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, Executive wishes to be employed by the Company as of the Effective Date.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">NOW THEREFORE, in consideration of the above recitals, which are incorporated herein, the mutual covenants and mutual benefits set forth herein, and other good and valuable consideration, the
        receipt and sufficiency of which is acknowledged, the Company and Executive agree as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Representations and Warranties.</font>&#160; Executive represents and warrants to the Company that Executive is not
        bound by any restrictive covenants or other obligations or commitments of any kind that would in any way prevent, restrict, hinder or interfere with Executive&#8217;s acceptance of employment under the terms and conditions set forth herein or the
        performance of all duties and services hereunder to the fullest extent of Executive&#8217;s ability and knowledge.&#160; Executive understands and acknowledges that Executive is not expected or permitted to use or disclose confidential information belonging
        to any prior employer in the course of performing Executive&#8217;s duties for the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Term of Employment.</font>&#160; As of the Effective Date, the Company will employ Executive and Executive accepts
        employment by the Company on the terms and conditions herein that shall commence on the Effective Date and shall continue until terminated pursuant to Section 5 (the &#8220;<font style="font-weight: bold; font-style: italic;">Employment Period</font>&#8221;).&#160;
        Notwithstanding anything set forth in Section 5 and for the avoidance of doubt, Executive&#8217;s employment is on an at-will basis, meaning that Executive or the Company can terminate Executive&#8217;s employment at any time for any reason or no reason, with
        or without notice.&#160; The at-will nature of Executive&#8217;s employment cannot be changed except by written agreement signed by Executive and the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Duties and Functions.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160; Executive shall be employed as the Chief Scientific Officer of the Company (&#8220;<font style="font-weight: bold; font-style: italic;">CSO</font>&#8221;) and shall report to the <a name="z_Hlk56192353"></a>Chief Executive Officer/President (the &#8220;<font style="font-weight: bold; font-style: italic;">Supervisor</font>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees to undertake the duties and responsibilities inherent in the position of CSO, which may encompass different or additional duties as may, from time to time, be assigned
        by his Supervisor, or the Supervisor&#8217;s designee, and the duties and responsibilities undertaken by Executive may be altered or modified from time to time by Supervisor, or by the Supervisor&#8217;s designee.&#160; Executive&#8217;s duties shall include but not be
        limited to those duties set forth on <u>Addendum A</u>.&#160; Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any change thereof which may be adopted at any time by the Company.
        Notwithstanding the foregoing, during the COVID-19 pandemic, business related travel will be subject to the Supervisor&#8217;s and Executive&#8217;s good faith determination that business related travel is necessary.&#160; All applicable COVID-19 travel
        restrictions, state, local and federal health and safety guidelines, and Company policies should be considered in connection with any travel activities.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-indent: 36pt;">During the Employment Period, Executive will devote Executive&#8217;s full time and efforts to the business of the Company and will not, without the consent of the Company, engage in consulting work or any trade or business
        for Executive&#8217;s own account or for or on behalf of any other person, firm or corporation that competes, conflicts or interferes with the performance of Executive&#8217;s duties hereunder in any way.&#160;&#160;However, Executive is permitted to engage in the
        activities listed in <u>Addendum D</u>, pursuant to the terms set forth in Addendum A and to the extent that he is not in violation of the terms of this Agreement or in breach of his fiduciary duties to the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-weight: bold;">Compensation.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Base Salary</u>:&#160; As compensation for Executive&#8217;s services hereunder, the Company agrees to pay Executive a base salary at an annual rate of $415,000, payable in accordance with the
        Company&#8217;s normal payroll schedule, but in no event less frequently than monthly.&#160; Executive&#8217;s base salary shall be reviewed annually by the Board or the Compensation Committee thereof and subject to increase from time to time in the Board&#8217;s and/or
        the Compensation Committee&#8217;s sole discretion.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Bonus</u>:&#160; Beginning with calendar year 2021, Executive shall be eligible to receive an annual cash bonus award in an amount to target 40% of his base salary upon achievement of
        reasonable performance targets set by the Board or the Compensation Committee thereof in its sole discretion.&#160; Such targets shall be based in part upon performance of the Company, and in part on Executive&#8217;s individual performance. The bonus shall
        be determined by the Board or the Compensation Committee thereof in its sole discretion and paid annually by March 15 of the year following the performance year on which such bonus is based.&#160; Except as contemplated by Section 5(c)(i) below,
        Executive&#8217;s receipt of the bonus, if any, is conditioned on Executive&#8217;s continued employment in good standing as of the date on which such bonus is paid, and any such bonus will not be considered earned until such payment date. Executive&#8217;s bonus
        opportunity shall be reviewed annually by the Board or the Compensation Committee thereof and subject to adjustment to reflect Executive&#8217;s performance in the Board&#8217;s and/or the Compensation Committee&#8217;s sole discretion.&#160;Executive&#8217;s bonus for 2021
        shall be prorated for the number of days of employment in calendar year 2021 from the Effective Date.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Equity Compensation</u>:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the Effective Date, in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, Executive shall be granted two
        equity awards covering the Company&#8217;s common stock (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Grant</font>&#8221;). The Grant shall have a grant date fair value for accounting purposes of $5,763,000 (the &#8220;<font style="font-weight: bold; font-style: italic;">Grant Value</font>&#8221;) and shall be apportioned among the two equity awards as set forth below using a 30-day volume-weighted average stock price as of the grant date and a restricted stock
        unit-to-option conversion factor of a stock option award covering two shares to a restricted stock unit award covering one share.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall grant Executive a time-based nonqualified stock option grant (the &#8220;<font style="font-weight: bold; font-style: italic;">Option Grant</font>&#8221;) covering a number of
        shares corresponding to one-half of the Grant Value using the methodology described above in Section 4(c)(i). The per share exercise price of the Option Grant shall equal the closing price of a share of the Company&#8217;s common stock on the grant date.
        The Option Grant shall vest as to twenty-five percent of the shares covered thereby on the first anniversary of the Effective Date, and 1/36 of the remaining shares covered thereby on each monthly anniversary of the Effective Date thereafter, in
        each case subject to Executive&#8217;s continued employment with the Company through the relevant vesting date. If the number of shares covered by the Option Grant using the methodology described above in Section 4(c)(i) is less than 115,020 shares, such
        number of shares shall be increased to 115,020 shares. If the number of shares covered by the Option Grant using the methodology described above in Section 4(c)(i) is greater than 140,580 shares, such number of shares shall be decreased to 140,580
        shares.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; The Company shall grant Executive a time-based restricted stock unit grant (the &#8220;<font style="font-weight: bold; font-style: italic;">RSU Grant</font>&#8221;) covering a number of shares of
        the Company&#8217;s common stock corresponding to one-half of the Grant Value using the methodology described above in Section 4(c)(i). The RSU Grant shall vest in four equal annual installments beginning on the first anniversary of the Effective Date,
        subject to Executive&#8217;s continued employment with the Company through the relevant vesting date, and shall be settled by March 15 of the year following the relevant vesting date. If the number of shares covered by the RSU Grant using the methodology
        described above in Section 4(c)(i) is less than 57,510 shares, such number of shares shall be increased to 57,510 shares. If the number of shares covered by the RSU Grant using the methodology described above in Section 4(c)(i) is greater than
        70,290 shares, such number of shares shall be decreased to 70,290 shares.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; All other terms and conditions of the Option Grant and the RSU Grant shall be the same as the Company&#8217;s standard forms of grant agreements.&#160; The Option Grant and the RSU Grant are each
        intended to constitute an &#8220;employment inducement grant&#8221; in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and are offered as an inducement material to Executive in
        connection with the Company&#8217;s hiring of Executive.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Commencing in 2022, Executive shall be eligible to receive an equity award under the applicable equity incentive plan of the Company as then in effect, as determined by the
        Compensation Committee based on Executive&#8217;s performance.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Other Expenses</u>:&#160; In addition to the compensation provided for above, the Company agrees to pay or to reimburse Executive during Executive&#8217;s employment for all reasonable,
        ordinary and necessary, properly documented, business expenses incurred in the performance of Executive&#8217;s services hereunder in accordance with Company policy in effect from time to time; provided, however, that the amount available to Executive
        for such travel, entertainment and other expenses may require advance approval from his Supervisor.&#160; Executive shall submit vouchers and receipts for all expenses for which reimbursement is sought.&#160; Notwithstanding any expense reimbursement policy
        of the Company that may then be in effect, Executive shall be entitled to reimbursement without advance approval by his Supervisor of the costs of (i) up to 4 professional conferences in an amount not to exceed $10,000 annually and (ii) all
        flights, which, when possible, shall be business class or better for all flights for Company travel over three hours in length.&#160; Executive shall also receive $50/month for costs associated with using his mobile device and home internet for business
        purposes pursuant to the Company&#8217;s Work From Home Device Use and Reimbursement Policy.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Paid Time Off and Paid Holidays</u>:&#160; Executive shall accrue up to 20 days of paid time off (&#8220;<font style="font-weight: bold; font-style: italic;">PTO</font>&#8221;) per year of
        employment, which shall accrue pro rata in the Company&#8217;s regular payroll (up to a maximum of 42 days).&#160; PTO shall accrue pro rata in the Company&#8217;s regular payroll on a calendar basis and shall be subject to the Company&#8217;s PTO policies in place from
        time to time and all applicable state and local law.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Any accrued, unused PTO can be carried over to the following calendar year up to a maximum of 60 days (the &#8220;Cap&#8221;).&#160;&#160; Once the Cap is reached, no further PTO will accrue until some accrued time is
        used.&#160; When some PTO is used, PTO will begin to accrue again.&#160; A portion of accrued, unused PTO may be paid upon separation of employment pursuant to Company policy and applicable law.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">In addition to the enumerated paid Company holidays, Executive shall also be entitled to up to seven (7) paid floating holidays per calendar year.&#160; Unused paid floating holidays shall expire on
        December 31 each year and shall not be paid upon separation.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Executive may also be entitled to additional paid or unpaid leave under Company policy and applicable law.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Fringe Benefits</u>.&#160; In addition to Executive&#8217;s compensation provided by the foregoing, Executive shall be entitled to all benefits available generally to Company employees pursuant
        to Company programs which may now or, if not terminated, shall hereafter be in effect, or that may be established by the Company, as and to the extent any such programs are or may from time to time be in effect, as determined by the Company <a name="mark"></a><a name="CurrSpot"></a>and the terms hereof, subject to the applicable terms and conditions of the benefit plans in effect at that time.&#160; Nothing herein shall affect the Company&#8217;s ability to modify, alter, terminate or otherwise
        change any benefit plan it has in effect at any given time, to the extent permitted by law.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Reimbursements</u>.&#160; With respect to any reimbursement of expenses of Executive, such reimbursement of expenses shall be subject to the following conditions: (i) the expenses
        eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which
        such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Termination.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Executive</u>. Executive may terminate the employment relationship at any time by giving the Company written notice, with such termination taking effect upon written
        notice of the termination being provided to the Company. If Executive chooses to terminate the employment relationship other than for Good Reason (defined below), Executive will not be entitled to and shall not receive any compensation or benefits
        of any type following the effective date of termination, other than (i) payment of base salary through the last day of employment, (ii) payment for any accrued but unused paid time off consistent with this agreement and the Company&#8217;s policies then
        in effect, (iii) reimbursement for unreimbursed business expenses properly incurred by Executive, which shall be subject to and paid in accordance with the Company&#8217;s expense reimbursement policy, and (iv) any right to continued benefits required by
        law or under the Company&#8217;s employee benefit plans and vested as of the termination date (the &#8220;Accrued Obligations&#8221;). If Executive terminates the employment relationship for Good Reason (defined below), Executive will be entitled to the Accrued
        Obligations and the Non-CIC Termination Compensation or CIC Termination Compensation, as applicable and described below, subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold; font-style: italic;">Good Reason</font>&#8221; means the occurrence of any of the following without Executive&#8217;s express written consent: (A) a material
        reduction in Executive&#8217;s base salary or maximum annual bonus, in each case set forth in Section 4; (B) a relocation of Executive to a facility or location that is more than fifty (50) miles from Executive&#8217;s primary place of employment as of the
        Effective Date and represents a material increase in Executive&#8217;s commuting distance; (C) a material diminution in Executive&#8217;s authority, position, duties, or responsibilities individually or taken as a whole and including any such diminution that
        takes place following a Change in Control; or (D) a material breach by the Company of the terms of this Agreement or any other agreement between the Company and Executive; provided, that no such event described above will constitute Good Reason
        unless: (x) Executive gives notice to the Company specifying the condition or event relied upon for such termination within sixty (60) days of the initial existence of such event; and (y) the Company fails to cure the condition or event
        constituting Good Reason within thirty (30) days following receipt of such notice (the &#8220;<font style="font-weight: bold; font-style: italic;">Cure Period</font>&#8221;).&#160; If the Company fails to remedy the condition constituting Good Reason during the
        applicable Cure Period, Executive&#8217;s termination of employment must occur, if at all, within ninety (90) days following the last day of such Cure Period in order for such termination as a result of such condition to constitute a termination for Good
        Reason.&#160; For purposes of this Agreement, &#8220;Change in Control&#8221; means as defined in the Company&#8217;s 2020 Stock Incentive Plan.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Company for Cause</u>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; At any time during the Employment Period, the Company may terminate Executive&#8217;s employment for Cause (defined below), with such termination taking effect upon the later of written
        notice of the termination for Cause being provided to Executive or the expiration of any applicable cure period related thereto (provided that Executive may be relieved from his duties hereunder during such cure period in the reasonable direction
        of the Board).&#160; If Executive&#8217;s employment is terminated for Cause, Executive will not be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, other than the Accrued Obligations, and
        shall forfeit the Option Grant and the RSU Grant, in each case whether vested or unvested.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Cause</font>&#8221; shall be defined as termination for:<font style="color: rgb(0, 0, 0);"> (A) in connection with Executive&#8217;s services
          hereunder, Executive commits a material act of fraud or material act of dishonesty with respect to the Company, which act causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (B)
          Executive is convicted of (or pleads guilty or nolo contendere to) a felony or a crime involving moral turpitude, which demonstrably causes material economic or material reputational harm to the Company; (C) Executive engages in negligence or
          willful misconduct in the performance of his duties hereunder that materially violates the Company&#8217;s policies and which misconduct causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company;
          (D) Executive willfully refuses to follow the lawful written directions of his Supervisor, the Supervisor&#8217;s designee, or the Board; (E) Executive materially breaches any material provision of any proprietary information and inventions agreement
          with the Company; or (F) Executive breaches any Restrictive Covenant as defined in Section 5(c)(ii).&#160; Notwithstanding anything in this Agreement or elsewhere to the contrary, if an event or occurrence that is alleged to constitute Cause is
          curable (as determined by the Board in good faith), the Company may terminate Executive&#8217;s employment for Cause only if (x) the Company gives Executive notice of termination prior to the termination and within thirty (30) days after the Board
          learns of the event or occurrence that is alleged to constitute Cause, specifying the grounds upon which Cause is alleged, (y) Executive fails to cure such grounds for Cause within thirty (30) days after Executive receives such notice, and (z)
          the termination occurs within sixty (60) days after such event or occurrence.&#160; For purposes of this Agreement, no act or failure to act, on Executive&#8217;s part, will be considered &#8220;willful&#8221; unless it is done, or omitted to be done, by Executive in
          bad faith or without reasonable belief that Executive&#8217;s action or omission was in the best interests of the Company.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination by Company Without Cause</u>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company may terminate Executive without Cause immediately by giving Executive written notice of such termination.&#160; Subject to the conditions set forth in Section 5(c)(ii), if
        Executive&#8217;s employment is terminated by the Company without Cause, in addition to the Accrued Obligations, Executive shall be entitled to (i) continued base salary for nine (9) months following date of such termination (the &#8220;<font style="font-weight: bold; font-style: italic;">Severance Period</font>&#8221;) paid pursuant to the Company's normal practices; and (ii) if Executive and/or Executive&#8217;s covered dependents timely elect(s) to receive health care continuation coverage
        pursuant to COBRA, the total monthly cost of coverage for Executive (and such covered dependents) during the Severance Period, provided, for the avoidance of doubt, that such covered dependents participated in the Company&#8217;s health plans prior to
        such termination, and provided, further, that if at any time the Company determines that its payment of Executive&#8217;s (or Executive&#8217;s eligible dependents&#8217;) premiums would result in a violation of law, then in lieu of providing the premiums described
        above, the Company will instead pay Executive a fully taxable monthly cash payment in an amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance
        Period (together, the &#8220;<font style="font-weight: bold; font-style: italic;">Non-CIC Termination Compensation</font>&#8221;). Notwithstanding the foregoing, if Executive&#8217;s employment is terminated by the Company without Cause or by Executive for Good
        Reason, in each case during the ninety (90) days prior to or twelve (12) month period following a Change in Control, (i) the Executive shall receive the Non-CIC Termination Compensation as described above except that the Severance Period shall
        equal twelve (12) months in lieu of nine (9) months, (ii) Executive shall receive a lump-sum payment of Executive&#8217;s target annual bonus and (iii) Executive shall become fully vested in the Option Grant and the RSU Grant (together, the &#8220;<font style="font-weight: bold; font-style: italic;">CIC Termination Compensation</font>&#8221;). The Non-CIC Termination Compensation and the CIC Termination Compensation shall, as applicable and in each case, be subject to the terms, conditions and
        restrictions set forth below in Section 5(c)(ii).</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive shall not be entitled to any Non-CIC Termination Compensation or CIC Termination Compensation unless (A) Executive complies with all surviving provisions of any
        non-competition agreement, non-solicitation agreement, or confidentiality agreement or invention assignment agreement signed by Executive, including those contained in this Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Restrictive

          Covenants</font>&#8221;) and (B) Executive executes and delivers to the Company, and does not revoke a separation agreement and general release in form and substance acceptable to the Company within thirty (30) days after Executive&#8217;s separation date,
        by which Executive releases the Company from any obligations and liabilities of any type whatsoever, except for the Company&#8217;s obligations with respect to, as applicable, the Non-CIC Termination Compensation or the CIC Termination Compensation (the
        &#8220;<font style="font-weight: bold; font-style: italic;">Release</font>&#8221;).&#160; Such Release shall not affect Executive&#8217;s right to indemnification, if any, for actions taken within the scope of Executive&#8217;s employment. The Non-CIC Termination Compensation
        or the CIC Termination Compensation, as applicable, shall begin, or if lump-sum, be paid on the first payroll following the Release becoming irrevocable; provided, however, if the thirty (30) day period during which Executive has discretion to
        execute or revoke the Release straddles two taxable years of Executive, then the Company shall pay the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, starting in the second of such taxable years, regardless of
        which taxable year Executive actually delivers the executed Release to the Company.&#160; The Parties hereto acknowledge that the Non-CIC Termination Compensation and the CIC Termination Compensation, as applicable, to be provided under Section 5(c)(i)
        is to be provided in consideration for the above-specified Release.&#160; If Executive breaches any of the Restrictive Covenants at any time during the Severance Period, (1) the Company will have no further obligation to pay Executive any unpaid Non-CIC
        Termination Compensation or CIC Termination Compensation, as applicable, (2) Executive must repay any portion of the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, already paid to him, and (3) the Company may
        take any additional action to enforce its rights under the Restrictive Covenants.&#160; Finally, if Executive becomes employed during the Severance Period, Executive will no longer be entitled to receive his continued base salary from the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; <u>Disqualification for Other Severance</u>.&#160; The Non-CIC Termination Compensation and the CIC Termination Compensation described in this Section 5(c) is intended to supersede any
        other similar compensation provided by any Company policy, plan or practice.&#160; Therefore, Executive shall be disqualified from receiving any similar compensation under any other Company severance policy, plan or practice, if any. Notwithstanding the
        foregoing, Executive shall continue to be eligible for any benefits pursuant to the terms of any health or retirement plan sponsored by the Company, subject to and in accordance with the terms of the applicable plan.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination for Executive&#8217;s Permanent Disability</u>.&#160; To the extent permissible under applicable law, in the event Executive becomes permanently disabled during employment with the
        Company, the Company may terminate this Agreement by giving thirty (30) days' notice to Executive of its intent to terminate, and unless Executive resumes performance of the duties set forth in Section 3 within five (5) days of the date of the
        notice and continues performance for the remainder of the notice period, this Agreement shall terminate at the end of the thirty (30) day period.&#160; For purposes of this Agreement, &#8220;permanently disabled&#8221; shall mean if Executive is considered totally
        disabled under any group disability plan maintained by the Company and in effect at that time, or in the absence of any such plan, under applicable Social Security regulations, to the extent not inconsistent with applicable law.&#160; In the event of
        any dispute under this Section 5(d), Executive shall submit to a physical examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such examination to be paid by the Company, and the determination of such
        physician shall be determinative.&#160; In the event the Executive is terminated pursuant to this Section 5(d), Executive will be entitled to the Accrued Obligations and the Non-CIC Termination Compensation, subject to the terms, conditions and
        restrictions set forth in Section 5(c)(ii).</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Termination Due to Executive&#8217;s Death</u>.&#160; This Agreement will terminate immediately upon Executive&#8217;s death and the Company shall not have any further liability or obligation to
        Executive, Executive&#8217;s executors, heirs, assigns or any other person claiming under or through Executive&#8217;s estate, except that Executive&#8217;s estate shall receive any Accrued Obligations. In addition, Executive&#8217;s estate shall be entitled to
        accelerated vesting of the portion of the Option Grant and the RSU Grant that would have otherwise vested during the nine (9) month period following such termination.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Continuing Obligations</u>.&#160; The obligations imposed on Executive with respect to non-competition, non-solicitation, confidentiality, non-disclosure and assignment of rights to
        inventions or developments in this Agreement or any other agreement executed by the Parties shall continue, notwithstanding the termination of the employment relationship between the Parties and regardless of the reason for such termination.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold;">Company Property.&#160; </font>All correspondence, records, documents, software, promotional materials, and other
        Company property, including all copies, which come into Executive&#8217;s possession by, through or in the course of Executive&#8217;s employment, regardless of the source and whether created by Executive, are the sole and exclusive property of the Company,
        and immediately upon the termination of Executive&#8217;s employment, or at any time the Company shall request, Executive shall return to the Company all such property of the Company, without retaining any copies, summaries or excerpts of any kind or in
        any format whatsoever.&#160; Executive shall not destroy any Company property, such as by deleting electronic mail or other files, other than in the normal course of Executive&#8217;s employment.&#160; Executive further agrees that should Executive discover any
        Company property or Confidential Information in Executive&#8217;s possession after the return of such property has been requested, Executive agrees to return it promptly to Company without retaining copies, summaries or excerpts of any kind or in any
        format whatsoever.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Non-Competition and Non-Solicitation.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees and acknowledges that, in connection with Executive&#8217;s employment with the Company, Executive will be provided with access to and become familiar with confidential and
        proprietary information and trade secrets belonging to the Company and its affiliates.&#160; Accordingly, in consideration of Executive&#8217;s employment with the Company pursuant to this Agreement, and other good and valuable consideration, the receipt of
        which is hereby acknowledged, Executive agrees that, while Executive is in the employ of the Company and/or any of its affiliates, Executive shall not, either on Executive&#8217;s own behalf or on behalf of any third party, except on behalf of the
        Company or one of its affiliates, directly or indirectly:</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;engage directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below) or directly or indirectly be or become an
        officer, director, stockholder, owner, affiliate, partner, member, investor, joint venture, employee, agent, representative, consultant, lender, advisor, manager of, for or to, or otherwise be or become associated with or acquire or hold (of
        record, beneficially or otherwise) any direct or indirect interest in, any business or enterprise engaged directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below).&#160; As used herein, (A) the
        term &#8220;<font style="font-weight: bold; font-style: italic;">Business</font>&#8221; shall mean the business of development and manufacturing of a cytokine immunotherapy (related to or derived from human source material) for cancer treatment and RNA based
        gene therapy and editing of MSC, HSC, TILs and T-Cells, and (B) the term &#8220;<font style="font-weight: bold; font-style: italic;">Restricted Territory</font>&#8221; shall mean worldwide.&#160; The foregoing restriction shall not be construed to prohibit the
        ownership by Executive as a passive investment of shares of capital stock of a publicly-held corporation that engages in the Business if (x) such shares are actively traded on an established national securities market in the United States or any
        other foreign securities exchange, (y) the number of shares of such corporation&#8217;s capital stock that are owned beneficially (directly or indirectly) by Executive and the number of shares of such corporation&#8217;s capital stock that are owned
        beneficially (directly or indirectly) by Executive&#8217;s affiliates collectively represent less than one percent (1%) of the total number of shares of such corporation&#8217;s capital stock outstanding, and (z) neither Executive nor any affiliate of
        Executive is otherwise associated directly or indirectly with such corporation or with any affiliate of such corporation;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; attempt in any manner to solicit, induce or attempt to induce any business, enterprise, or individual who has a business relationship with the Companies (including
        any customer, licensee, supplier, manufacturer or vendor) (x) to cease doing business with the <a name="z_Hlk56193364"></a>Company or any of its affiliates, (y) to diminish or materially alter in a manner harmful to the Company or any of its
        affiliates, or any of their affiliates such business, enterprise, or individual&#8217;s relationship with the Company or any of its affiliates, or (z) to purchase, contract for or receive any products or services from any business or enterprise (other
        than the Company or any of its affiliates) that engages in the Business anywhere within the Restricted Territory; or</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees and acknowledges that for one (1) year period following the end of Executive&#8217;s employment for any reason,&#160; Executive shall not, either on Executive&#8217;s own behalf or on
        behalf of any third party (A) directly or indirectly hire any employee, independent contractor, or consultant or any person who was an employee, independent contractor, or consultant of the Companies within the preceding six (6) months, or (B)
        directly or indirectly encourage, induce, attempt to induce, solicit or attempt to solicit (on Executive&#8217;s own behalf or on behalf of any other business, enterprise, or individual) any employee, independent contractor, or consultant to leave or
        curtail his or her employment or engagement with the Company or any of its affiliates; provided, however, that notwithstanding the foregoing, this Section 7(a)(iii) shall not prevent Executive from undertaking general solicitations of employment
        not targeted at employees, independent contractors, or consultants of the Company or any of its affiliates (so long as Executive does not, directly or indirectly, hire any such employee, independent contractor, or consultant).</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Parties agree that the relevant public policy aspects of post-employment restrictive covenants have been discussed, and that every effort has been made to limit the restrictions
        placed upon Executive to those that are reasonable and necessary to protect the Company&#8217;s legitimate interests.&#160; Executive acknowledges that, based upon Executive&#8217;s education, experience, and training, the restrictions set forth in this Section 7
        will not prevent Executive from earning a livelihood and supporting himself and Executive&#8217;s family during the relevant time period.&#160; Executive further acknowledges that, because the Company markets its products and services throughout the
        Restricted Territory, a more narrow geographic limitation on the restrictive covenants set forth above would not adequately protect the Company&#8217;s legitimate business interests.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any restriction set forth in this Section 7 is found by any court of competent jurisdiction or arbitrator to be unenforceable because it extends for too long a period of time or
        over too great a range of activities or geographic area, it shall be interpreted to extend over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The restrictions contained in Section 7 are necessary for the protection of the business and goodwill of the Company and/or its affiliates and are considered by Executive to be
        reasonable for such purposes.&#160; <a name="z_Hlk55783292"></a>Executive agrees that any material breach of Section 7 will result in irreparable harm and damage to the Company and/or its affiliates that cannot be adequately compensated by a monetary
        award.&#160; Accordingly, it is expressly agreed that in addition to all other remedies available at law or in equity (including, without limitation, money damages from Executive), the Company and/or such affiliate shall be entitled to a temporary
        restraining order, preliminary injunction or such other form of injunctive or equitable relief as may be issued by any court of competent jurisdiction or arbitrator to restrain or enjoin Executive from breaching any such covenant or provision or to
        specifically enforce the provisions hereof, without the need to post any bond or other security.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The existence of a claim, charge, or cause of action by Executive against the Company shall not constitute a defense to the enforcement by the Company of the foregoing restrictive
        covenants.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of this Section 7 shall apply regardless of the reason for the termination of Executive&#8217;s employment.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Non-Circumvention / Non-Interference.&#160; </font>Executive acknowledges and agrees that during the Employment
        Period, Executive shall not, and shall not authorize or permit any of his Representatives to, directly or indirectly, interfere, discuss, contact, initiate, or engage, encourage, solicit, initiate, facilitate or continue inquiries to any third
        parties concerning any business opportunities related to the Company.&#160; It is understood that, during the Employment Period, without previous written consent from the Company, the Executive&#160; will not enter, either directly or indirectly, into any
        discussions, solicit or accept offers, enter into any agreements, conduct negotiations with or otherwise engage in any other independent communications with: any third party to whom Executive was introduced to by any member, shareholder, officer,
        director, employee, agent, customer, supplier, vendor, or other representative of the Company, Factor Bioscience, or Novellus, Inc.; any third party to whom Executive was informed of by any member, shareholder, officer, director, employee, agent,
        customer, supplier, vendor, or other representative of Company, Factor Bioscience, or Novellus, Inc. or any employee, financial partner, investor, contractor of the Company. For purposes of this Agreement, "Representatives" means, as to Company,
        its affiliates, and respective consultants (including attorneys, financial advisors and accountants).&#160; Further, after termination of Executive&#8217;s employment with the Company, he will not interfere with existing contractual and or business
        relationships with the Company in a manner prohibited by law.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Protection of Confidential Information.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Executive agrees that all information, whether or not in writing, relating to the business, technical or financial affairs of the Company and that is generally understood in the industry
        as being confidential and/or proprietary information, is the exclusive property of the Company.&#160; Executive agrees to hold in a fiduciary capacity for the sole benefit of the Company all secret, confidential and/or proprietary information,
        knowledge, and data, including trade secrets, relating to the Company or any of its affiliates obtained during Executive&#8217;s employment with the Company or any of its predecessors or affiliates, including but not limited to any trade secrets,
        confidential or secret designs, website technologies, content, processes, formulae, plans, manuals, devices, machines, know-how (including without limitation the manufacturing of IRX-2), methods, compositions, ideas, improvements, financial and
        marketing information, costs, pricing, sales, sales volume, salaries, methods and proposals, customer and prospective customer lists, customer identities, customer volume, or customer contact information, identity of key personnel in the employ of
        customers and prospective customers, amount or kind of customer&#8217;s purchases from the Companies or their affiliates, manufacturer lists, manufacturer identities, manufacturer volume, or manufacturer contact information, identity of key personnel in
        the employ of manufacturers, amount or kind of the Companies&#8217; or their affiliates&#8217; purchases from manufacturers, system documentation, hardware, engineering and configuration information, computer programs, source and object codes (whether or not
        patented, patentable, copyrighted or copyrightable), related software development information, inventions or other confidential or proprietary information (including without limitation information relating to IRX-2 and its intellectual property
        that has not yet issued) belonging to the Companies or their affiliates or directly or indirectly relating to the Companies&#8217; or their affiliates&#8217; business and affairs (&#8220;<font style="font-weight: bold; font-style: italic;">Confidential Information</font>&#8221;).&#160;

        Executive agrees that Executive will not at any time, either during the Employment Period or the Confidentiality Period (as defined below), disclose to anyone any Confidential Information, or utilize such Confidential Information for Executive&#8217;s
        own benefit, or for the benefit of third parties without written approval by an officer of the Company.&#160; For purposes of this section, the &#8220;<font style="font-weight: bold; font-style: italic;">Confidentiality Period</font>&#8221; means so long as such
        information, data, or material remains confidential.&#160; Executive further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs, prototypes, or written, photographic, magnetic or other documents or tangible objects
        compiled by Executive or made available to Executive during the Employment Period concerning the business of the Company and/or its clients, including any copies of such materials, shall be the property of the Company and shall be delivered to the
        Company on the termination of Executive&#8217;s employment, or at any other time upon request of the Company.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to
        any Confidential Information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, or in the event that Executive becomes aware of the unauthorized use of Confidential Information by any
        party, whether competitive with the Company or not, Executive will promptly notify an executive officer of the Company.</div>
      <div style="text-align: justify; text-indent: 72pt;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Confidential and Proprietary Information of Others</u>. Executive acknowledges that the Company has a strict policy against using confidential or proprietary information belonging to
        any other person or entity without the express permission of the owner of that information. Executive represents and warrants that the performance by Executive of all of the terms of this Agreement will not result in any breach of any duty owed by
        Executive to ViaCyte, Inc. or any other third party to keep in confidence or not to use any confidential or proprietary information, knowledge or data acquired by Executive in confidence. Executive agrees not to disclose to the Company or to induce
        the Company to use any confidential or proprietary information belonging to any third party. Executive will not, at any time, disclose to, or discuss with, the Company employees any confidential or proprietary data belonging to Executive&#8217;s former
        employers, nor will Executive bring to the Company&#8217;s premises any confidential or proprietary information belonging to Executive&#8217;s former employers, ViaCyte, Inc., or any other third party, and will not disclose or use any such information while
        performing work for the Company. Executive agrees to indemnify and hold harmless the Company for any damages whether monetary, punitive, or in equity caused by or the result of Executive&#8217;s disclosure of confidential or proprietary information or
        any confidential information belonging to Executive&#8217;s former employers, ViaCyte, Inc., or other entities or persons with whom Executive has a duty to not disclose confidential or proprietary information.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Court-Ordered Disclosure</u>.&#160; In the event that, at any time during Executive&#8217;s employment with the Company or at any time thereafter, Executive receives a request to disclose&#160; any
        Confidential Information under the terms of a subpoena or order issued by a court or by a governmental body, Executive agrees to notify the Company immediately of the existence, terms, and circumstances surrounding such request, to consult with the
        Company on the advisability of taking legally available steps to resist or narrow such request; and, if disclosure of such Confidential Information is required to prevent Executive from being held in contempt or subject to other penalty, to furnish
        only such portion of the Confidential Information as, in the written opinion of counsel satisfactory to the Company, Executive is legally compelled to disclose, and to exercise Executive&#8217;s best efforts to obtain an order or other reliable assurance
        that confidential treatment will be accorded to the disclosed Confidential Information.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Defend Trade Secrets Act</u>.&#160; Pursuant to the Defend Trade Secrets Act of 2016, Executive acknowledges that Executive shall not have criminal or civil liability under any federal or
        state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or
        investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Executive files a demand for arbitration alleging retaliation by
        the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the arbitration proceeding, if Executive (X) files any document containing the trade
        secret under seal and (Y) does not disclose the trade secret, except pursuant to an order of the arbitrator.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Intellectual Property.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Disclosure of Inventions</u>.&#160; Executive will promptly disclose in confidence to the Company all inventions, improvements, processes, products, designs, original works of
        authorship, formulas, processes, compositions of matter, computer software programs, Internet products and services, e-commerce products and services, e-entertainment products and services, databases, mask works, trade secrets, product
        improvements, product ideas, new products, discoveries, methods, software, uniform resource locators or proposed uniform resource locators (&#8220;<font style="font-weight: bold; font-style: italic;">URLs</font>&#8221;), domain names or proposed domain names,
        any trade names, trademarks or slogans, which may or may not be subject to or able to be patented, copyrighted, registered, or otherwise protected by law (the &#8220;<font style="font-weight: bold; font-style: italic;">Inventions</font>&#8221;) that Executive
        makes, conceives or first reduces to practice or creates, either alone or jointly with others, during the period of Executive&#8217;s employment, whether or not in the course of Executive&#8217;s employment (i) that result from any work performed by the
        Executive for the Company; (ii) that are developed from using the Company's equipment, supplies, facilities or trade secret information; or (iii) that relate at the time of conception or reduction to practice of the invention to the Company's
        business, or actual or demonstrably anticipated research or development of the Company.&#160; The requirements of this Section 10(a) shall not apply to any Inventions that qualify fully under the provisions of California Labor Code section 2870 (the
        terms of which are set forth on <u>Addendum B</u> to this Agreement), specifically, any Invention that Executive developed entirely on Executive&#8217;s own time without using the Employer&#8217;s equipment, supplies, facilities, or trade secret information
        except for those Inventions that either (i) relate at the time of conception or reduction to practice of the Invention to the Employer&#8217;s business, or Employer&#8217;s actual or demonstrably anticipated research or development; or (ii) result from any
        work performed by Executive for Employer.&#160; Executive shall bear the full burden of proving to the Employer that an Invention qualifies fully under section.&#160; The foregoing requirements of Section 10(a) apply, and whether or not such Inventions are
        patentable, copyrightable or able to be protected as trade secrets, or otherwise able to be registered or protected by law. Executive has provided a list of prior Inventions as <u>Addendum C</u>, which will not be subject to the provisions of this
        Section 10.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment of Company Inventions; Work for Hire</u>.&#160; Executive agrees that all Inventions that (i) are developed using equipment, supplies, facilities or trade secrets of the
        Company, (ii) result from work performed by Executive for the Company, or (iii) relate to the Company&#8217;s business or current or anticipated research and development (the &#8220;<font style="font-weight: bold; font-style: italic;">Company Inventions</font>&#8221;),

        will be the sole and exclusive property of the Company and the Executive hereby agrees to irrevocably assign to the Company any such Company Inventions.&#160; Executive further acknowledges and agrees that any copyrightable works prepared by Executive
        within the scope of Executive&#8217;s employment are &#8220;works for hire&#8221; under the Copyright Act and that the Company will be considered the author and owner of such copyrightable works from the moment of their creation and fixation in tangible media.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment of Other Rights</u>.&#160; In addition to the foregoing assignment of Company Inventions to the Company, Executive hereby irrevocably transfers and assigns to the Company:&#160;
        (i) all worldwide patents, patent applications, copyrights, mask works, trade secrets and other intellectual property rights in any Company Invention; and (ii) any and all &#8220;Moral Rights&#8221; (as defined below) that Executive may have in or with respect
        to any Company Invention.&#160; Executive also hereby forever waives and agrees never to assert any and all Moral Rights Executive may have in or with respect to any Company Invention, even after termination of Executive&#8217;s work on behalf of the
        Company.&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Moral Rights</font>&#8221; means any rights to claim authorship of an Company Invention, to object to or prevent the modification of any Company Invention, or to withdraw from circulation or
        control the publication or distribution of any Company Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated or generally
        referred to as a &#8220;moral right.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assistance</u>.&#160; Executive agrees to assist the Company in every proper way to obtain for the Company and enforce patents, copyrights, mask work rights, trade secret rights and other
        legal protections for the Company Inventions in any and all countries.&#160; Executive will execute any documents that the Company may reasonably request for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and
        other legal protections.&#160; Executive&#8217;s obligations under this section will continue beyond the termination of Executive&#8217;s employment with the Company, provided that the Company will compensate Executive at a reasonable rate after such termination
        for time or expenses actually spent by Executive at the Company&#8217;s request on such assistance.&#160; Executive appoints the Secretary of the Company as Executive&#8217;s attorney-in-fact to execute documents on Executive&#8217;s behalf for this purpose.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Publicity; Non-disparagement.&#160; </font>Neither Party shall issue, without consent of the other Party, any press
        release or make any public announcement with respect to this Agreement or the employment relationship between them, or the ending of such relationship.&#160; Following the date of this Agreement and regardless of any dispute that may arise in the
        future, Executive agrees that Executive will not disparage, criticize or make statements which are negative, detrimental or injurious to Company or any of its affiliates, or any of their affiliates to any individual, company or client, including
        within the Company.<a name="z_Ref1826681"></a>&#160; This <u>Section 11</u> does not, in any way, restrict or impede the parties hereto from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with
        any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation, or order.&#160; Nothing contained herein shall
        prevent Executive from providing true testimony to the extent required within any legal proceeding (or in any discovery in connection therewith) or investigation by a governmental authority.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Binding Agreement.</font>&#160; This Agreement shall be binding upon and inure to the benefit of the Parties hereto,
        their heirs, personal representatives, successors and assigns.&#160; Executive acknowledges and agrees that the Company may, in its sole discretion, assign this Agreement (i) to an affiliate of the Company at any time, or (ii) in the event the Company
        is acquired, is a non-surviving party in a merger, or transfers substantially all of its assets, to the transferee or surviving company, in each case without being required to obtain Executive&#8217;s consent.&#160; The Parties understand that the obligations
        of Executive are personal and may not be assigned by him.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">13.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Entire Agreement.</font>&#160; This Agreement contains the entire understanding of Executive and the Company with
        respect to employment of Executive.&#160; This Agreement may not be amended, waived, discharged or terminated orally, but only by an instrument in writing, specifically identified as an amendment to this Agreement, and signed by all Parties.&#160; By
        entering into this Agreement, Executive certifies and acknowledges that Executive has carefully read all of the provisions of this Agreement and that Executive voluntarily and knowingly enters into said Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Severability.</font>&#160; Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction
        shall, as to such jurisdiction, be deemed severable from the remainder of this Agreement, and the remaining provisions contained in this Agreement shall be construed to preserve to the maximum permissible extent the intent and purposes of this
        Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Tax Consequences</font>.&#160; If any payment or benefit the Executive would receive pursuant to this Agreement (<font style="font-weight: bold; font-style: italic;">&#8220;Payment&#8221;</font>) would (a) constitute a &#8220;<font style="font-weight: bold; font-style: italic;">Parachute Payment</font>&#8221; within the meaning of Section 280G of the Code, and (b) but for this sentence,
        be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;<font style="font-weight: bold; font-style: italic;">Excise Tax</font>&#8221;), then such Payment shall be equal to the Reduced Amount.&#160; The &#8220;<font style="font-weight: bold; font-style: italic;">Reduced Amount</font>&#8221; shall be either (i) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (ii) the largest portion, up to and including the total of the
        Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#8217;s receipt, on an
        after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.&#160; If a reduction in payments or benefits constituting Parachute Payments<font style="font-weight: bold;">&#160;</font>is

        necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive to the extent permitted by Section 409A of the Code, to the extent applicable, and Section 280G
        of the Code.&#160; Except as otherwise specifically provided in this Agreement, the Company will have no obligation to any person entitled to the benefits of this Agreement with respect to any tax obligation any such person incurs as a result of or
        attributable to this Agreement, including all supplemental agreements and employee benefits plans incorporated by reference therein, or arising from any payments made or to be made under this Agreement or thereunder.&#160; All determinations under this
        <font style="font-weight: bold;">Section 15</font> will be made by an actuarial firm, accounting firm, law firm, or consulting firm experienced and generally recognized in 280G matters (the &#8220;<font style="font-weight: bold;">280G Firm</font>&#8221;) that
        is chosen by the Company prior to a change in ownership or control of a corporation (within the meaning of Treasury regulations under Section 280G of the Code). The 280G Firm shall be required to evaluate the extent to which payments are exempt
        from Section 280G as reasonable compensation for services rendered before or after the Change in Control. All fees and expenses of the 280G Firm shall be paid solely by the Company or its successor. The Company and Executive shall furnish the tax
        firm such information and documents as the tax firm may reasonably request in order to make its required determination.&#160; The 280G Firm will provide its calculations, together with detailed supporting documentation, to the Company and Executive as
        soon as practicable following its engagement.&#160; Any good faith determinations of the 280G Firm made hereunder will be final, binding and conclusive upon the Company and Executive.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Withholding.&#160; </font>The Company shall have the right to withhold from any amount payable hereunder any
        federal, state, local and foreign taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation. Notwithstanding any other provision of this Agreement, the Company does not guarantee any
        particular tax result for Executive with respect to any payment provided to Executive hereunder, and Executive shall be solely responsible for any taxes imposed on Executive with respect to any such payment.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Section 409A.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Code and any regulations and Treasury guidance promulgated thereunder (&#8220;<font style="font-weight: bold; font-style: italic;">Section 409A of the Code</font>&#8221;) and shall be construed and administered in accordance with such intent.&#160; Notwithstanding any other provision of this Agreement, payments provided under this
        Agreement may only be made upon an event and in a manner that complies with Section 409A of the Code or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A of the Code either as separation pay due to an
        involuntary separation from service or as a short-term deferral shall be excluded from Section 409A of the Code to the maximum extent possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits
        provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Executive on account of
        non-compliance with Section 409A of the Code.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.&#160; In no event
        may Executive, directly or indirectly, designate the calendar year of payment.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160; With respect to any reimbursement of expenses of, or any provision of in-kind benefits to, Executive, as specified under this Agreement, such reimbursement of expenses or provision of
        in-kind benefits shall be subject to the following conditions: (1) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of
        in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made
        no later than the end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;Termination of employment,&#8221; &#8220;resignation,&#8221; or words of similar import, as used in this Agreement means, for purposes of any payments under this Agreement that are payments of deferred
        compensation subject to Section 409A of the Code, Executive&#8217;s &#8220;separation from service&#8221; as defined in Section 409A of the Code.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160; If a payment obligation under this Agreement arises on account of Executive&#8217;s separation from service while Executive is a &#8220;specified employee&#8221; (as defined under Section 409A of the Code
        and determined in good faith by the Company), any payment of &#8220;deferred compensation&#8221; (as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12))
        that is scheduled to be paid within six (6) months after such separation from service shall accrue without interest and shall be paid within fifteen (15) days after the end of the six-month period beginning on the date of such separation from
        service or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Executive&#8217;s estate following Executive&#8217;s death.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">18.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Governing Law.</font>&#160; This Agreement shall be governed by, and construed and enforced in accordance with, the
        laws of New York, without giving effect to the principles of conflicts of law thereof.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">19.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Notices.&#160; </font>Any notice provided for in this Agreement shall be provided in writing.&#160; Notices shall be
        effective from the date of service, if served personally on the Party to whom notice is to be given, or on the second day after mailing, if mailed by first class mail, postage prepaid.&#160; Notices shall be properly addressed to the Parties at their
        respective addresses or to such other address as either Party may later specify by notice to the other.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">20.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Dispute Resolution.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160; Executive and the Company mutually agree that any controversy or claim arising out of or relating to this Agreement or the employment relationship between Executive and the Company,
        including any dispute regarding the scope or enforceability of this arbitration provision, shall be settled by individual arbitration administered by Judicial Arbitration and Mediation Services (JAMS) in accordance with the JAMS Employment
        Arbitration Rules and Procedures in effect as of the date of this Agreement (&#8220;<u>JAMS Rules</u>&#8221;), to the extent the JAMS Rules are consistent with the terms of this provision. Judgment on the award may be entered in any court having jurisdiction
        thereof.&#160; The parties also mutually agree that, except as otherwise required by enforceable law, arbitration shall be the sole and exclusive forum for resolving such disputes (including any dispute with the Company, any related parties, and any of
        their respective employees, officers, owners or agents, who shall be third-party beneficiaries of this provision), and both parties agree that they are hereby waiving any right to have their disputes resolved in civil litigation by a court or jury
        trial, including but not limited to any disputes arising under statutes such as Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, or the California Fair Employment and Housing Act.&#160; The arbitrator&#8217;s decisions on such
        matters shall be final and binding on the parties to the fullest extent permitted by law.&#160; The JAMS Rules are incorporated herein by reference, to the extent they are consistent with the terms of this provision, and may be found at available at
        https://www.jamsadr.com/rules-employment-arbitration/.&#160; The place of arbitration shall be New York County, New York.&#160; Any arbitration hereunder shall be conducted only on an individual basis and not in a class, consolidated, or representative
        action.&#160; The Company shall pay the administrative costs and fees directly related to the arbitration, including the fees of the arbitrator.&#160; Each party shall otherwise bear its own respective attorneys&#8217; fees and costs, including the costs of any
        depositions or for expert witnesses, unless any applicable law provides otherwise to the prevailing party, in which case the arbitrator shall have the authority to award costs and attorneys&#8217; fees to the prevailing party in accordance with the
        applicable law.&#160; Neither a party nor the arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both parties, unless otherwise provided by law.&#160; The parties&#8217; agreement to
        arbitrate does not apply to claims that, pursuant to applicable law, cannot be subject to mandatory arbitration, including claims under the Private Attorney General Act; provided that, in the event of a dispute regarding whether, or the extent to
        which, any dispute is subject to arbitration, the parties agree that no underlying dispute or any facts regarding such dispute shall be submitted to a court until and unless a declaratory judgment is issued by the duly appointed arbitrator that
        allows a dispute to proceed in court based on a claim by a party that this arbitration provision is unenforceable as a matter of law as to an asserted claim.&#160; Moreover, nothing in this Agreement prevents Executive from filing or prosecuting a
        charge with any government agency (such as the Equal Employment Opportunity Commission) over which such agency has jurisdiction, or from participating in an investigation or proceeding conducted by any such agency. Any matter required to be
        arbitrated under this Section 20 shall be submitted to mediation in a manner agreed to by Executive and the Company.&#160; Executive and the Company agree to use mediation to attempt to resolve any such matter prior to filing for arbitration.&#160; Executive
        and the Company will select a mediator agreeable to both parties.&#160; The costs of the mediation and fees of the mediator will be borne entirely by the Company.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-weight: bold;">BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY WAIVE THE RIGHT TO BRING AND/OR PARTICIPATE IN ANY CLASS OR COLLECTIVE ACTION. THE ARBITRATOR SHALL HAVE NO POWER TO
        ARBITRATE ANY CLASS AND/OR COLLECTIVE CLAIMS. BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY ARE WAIVING THEIR STATUTORY AND COMMON LAW RIGHTS TO SEEK RELIEF IN A COURT OF LAW AND ARE WAIVING THEIR RIGHTS TO A TRIAL BY JURY.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the provisions of Section 20(a), the Parties further acknowledge and agree that, due to the nature of the confidential information, trade secrets, and intellectual
        property belonging to the Company to which Executive has or will be given access, and the likelihood of significant harm that the Company would suffer in the event that such information was disclosed to third parties, the Company shall have the
        right to file suit&#160; in a court of competent jurisdiction to seek injunctive relief to prevent Executive from violating the obligations established in Sections 7, 8, 9 or 10 of this Agreement without first submitting the&#160; claim, controversy, or
        dispute to JAMS mediation or arbitration.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">21.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Indemnification.</font>&#160; The Company shall indemnify and hold harmless Executive for any liability to any
        third-party incurred by reason of any act or omission performed by Executive while acting in good faith on behalf of the Company and within the scope of the authority of Executive pursuant to this Agreement and under the rules and policies of the
        Company, except that Executive must have in good faith believed that such action was in the best interest of the Company and such course of action or inaction must not have constituted gross negligence, fraud, willful misconduct, or breach of a
        fiduciary duty.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">22.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Miscellaneous.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Compensation Recovery Policy. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant to the Dodd-Frank Wall Street Reform and
        Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder, he or she shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into any further agreements,
        amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to past, present and future compensation, as appropriate).</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.&#160; A waiver or consent given by the Company on any
        one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The language in all parts of this Agreement will be construed, in all cases, according to its fair meaning, and not for or against either Party hereto.&#160; The Parties acknowledge that
        each Party and its counsel have reviewed and revised this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting Party will not be employed in the interpretation of this
        Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The obligations of Company under this Agreement, including its obligation to pay the compensation provided for in this Agreement, are contingent upon Executive&#8217;s performance of
        Executive&#8217;s obligations under this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which shall constitute one agreement.</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Signatures on following page]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>IN WITNESS WHEREOF, Executive and the undersigned duly authorized representative of the Company have executed this Agreement as of the date first above written.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z22cdc0f895a546d9abae5190d58847db" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">EXECUTIVE</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ Kevin D&#8217;Amour, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Kevin D&#8217;Amour, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: middle;">&#160;</td>
            <td style="width: 46%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: bottom;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 46%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ Howard J. Federoff, MD, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">&#160;</td>
            <td style="width: 46%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Howard J. Federoff, MD, PhD</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 4%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 46%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Chief Executive Officer/President</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">[<font style="font-style: italic;">Signature Page to Employment Agreement</font>]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>ADDENDUM A</u></div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">Job Duties</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb5f177ca595b4bcaafa5298f0f997a82" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Collaborates with the management team to set company research and scientific priorities to match the overall clinical mission and strategic goals of the company</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8ad72eba7b9044d1a49f60aed07b8f41" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Stays updated on technological advances and industry trends to in scientific matters</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z36652f7b04d8486a84880e55c51ed106" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides recommendations for future projects, necessary technologies, and opportunities</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf7ebe962b2b0465fbfc31b867036c1cc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides leadership for the scientific activities in the company</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb39f088e620644f59b6e89f51a91b752" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Communicates scientific experimental design and results to other managers and in collaboration with the CEO, as the CEO&#8217;s discretion, to the BOD</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1eddc8b198234a5c8c944125a82061ed" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Collaborates with the CFO, CMO, COO and VP R&amp;D and provides leadership to develop budgets for research and development projects, including main focus and additional projects</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb491d8448b4642e5b3ec69c91145b55b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Approves spending for responsible teams within predetermined budgetary parameters</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z77ac2ace2e1e4a289bdb9139685416b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Oversees, supports, and mentors all reporting personnel, maintaining a high level of commitment by and to employees</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6e2da874e3e54deaa793f8d2757009d3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Collaborates with the broader project team to ensure alignment of resource requirements in preclinical, clinical, and commercialization phases</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6f728f02e79448bb9351d263526f822c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>May participate, as needed, in regulatory strategy development, regulatory filings and meetings with regulatory agencies</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6b76f306ec254da0bf57ef5af6948095" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Responsible for drafting, submitting grants and progress reports for granting agencies that align with the priorities of the company.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z82775e61b36040e4aeedfc8d50866e84" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Participates in fundraising through presentations to investors and networking with contacts, as needed by the company</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zd11df03f26404cf39e395b4c2c9dde15" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides leadership for the scientific research agenda within the company and may be the point person, depending on the external entity, for outside collaborations with the company</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z14a7a7c60af8422cb940b382a94c1c96" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides leadership and collaborates with other R&amp;D leadership and others in the orchestration of patent applications and scientific publications</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zaad3642c9f784d34b3d13afae850e4de" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Collaborates as an management team member with manufacturing, business development, regulatory, finance, and clinical functions</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z948256bd45b445fd9cd8c6eeff111e1c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Chairs SAB, communicates with SAB, collates recommendations and disseminates for SAB meetings and encourages sub-meetings between SAB members and scientific and clinical staff, and endorses this work product be presented by sub-meeting
                leads to the SAB</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze7460303f02f415cb87cb2d3fe5bd6d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Responsible for identifying grant opportunities aligned with Brooklyn priorities, sharing these with the management team</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z97b6be90e4e246bbb46f6d4a4bce82ce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Partner with the CMO and other company clinical experts in external collaborations</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z5a5bc271654e40e9a609cd2404f5d94a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>When a grant opportunity is endorsed, the CSO is responsible for the drafting the proposal along with other management colleagues and others within the company, and the submission of endorsed grants for non-dilutive funding aligned with
                company strategic priorities</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zcbf2b2f4a7e042cf91e42c9709881389" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Represent and support Brooklyn in interactions with the FDA, EMA, MHRA, and other regulatory bodies</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zab98fcc63bb646b3a51b4003ac1aa701" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides leadership for the recruitment of qualified researchers, manages personnel in the span of reporting and evaluates their performance in compliance with company guidelines</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z1c2e797850524c77820be2a80901a52c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Supports the CEO, as needed, in representing the company at industry conferences</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z18f4df6ae47e4dcdbefce8c37fe0a488" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Provides leadership, in collaboration with others, to ensure that the company&#8217;s best efforts are represented when presentations at scientific meetings are scheduled</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z97381cd3f36b4bab92ec0963e7274e63" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Collaborates with the management team, notably leadership of Manufacturing, the CMO, and regulatory consultants and/or Brooklyn regulatory leaders and to review changes in global regulations and industry practices for the development and
                approval of cell therapy products</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zc9f6712664d24a3fa722f4043c35046d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Maintain a high standard of internal scientific practices</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z413fc62625d34965baf220f95e1342f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Sustain, along with other scientists, the company&#8217;s excellent scientific reputation</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8fd747023fa44e63a56d8b82c699d543" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div>May perform other duties and responsibilities as assigned</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>ADDENDUM B</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CALIFORNIA LABOR CODE SECTION 2870</div>
      <div><br>
      </div>
      <div style="margin-right: 7.2pt;">Section 2870 of the California Labor Code provides as follows:</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-right: 7.2pt;">(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an
        invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</div>
      <div>&#160;</div>
      <div style="margin-right: 7.2pt; margin-left: 72pt;">(1) Relate at the time of conception or reduction to practice of the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer; or</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-right: 7.2pt; margin-left: 36pt;">(2) Result from any work performed by the employee for the employer.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; margin-right: 7.2pt;">(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the
        provision is against the public policy of this state and is unenforceable.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>ADDENDUM D</u></div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OUTSIDE ACTIVITIES OF EXECUTIVE</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 7.2pt;">For a period of 1-year from the effective date of the Agreement, the Company shall permit Executive to serve as a consultant to ViaCyte, Inc.&#160; Executive agrees and acknowledges that he will not
        bring, use, or rely upon, or induce the Company to use or rely upon, any of ViaCyte, Inc.&#8217;s confidential or proprietary information or otherwise violate Section 9(c) of the Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 7.2pt;">Executive&#8217;s work for ViaCyte, Inc. must not exceed 10 hours of time per calendar month.&#160; Notwithstanding the foregoing, if Executive&#8217;s Supervisor determines, at his sole discretion, that
        Executive&#8217;s activities for ViaCyte, Inc. interfere with, conflict with, or otherwise harm the Company&#8217;s business, violates the terms of the Agreement, or breaches Executive&#8217;s fiduciary duties to the Company, Executive must immediately cease or
        decrease his activities for ViaCyte, Inc. at his Supervisor&#8217;s direction.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>brhc10025686_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="font-weight: bold; text-align: right;">Exhibit 99.1<br>
    </div>
    <div><br>
    </div>
    <div>
      <div><img src="image00001.jpg"></div>
      <div>&#160;</div>
      <div style="text-align: center;"><a name="z_DV_M0"></a><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Brooklyn ImmunoTherapeutics Welcomes</div>
      <div style="text-align: center; font-weight: bold;">Dr. Kevin A. D&#8217;Amour as Chief Scientific Officer</div>
      <div><br>
      </div>
      <div><a name="z_DV_M3"></a><font style="font-weight: bold;">Brooklyn, NY</font> &#8211; June 8, 2021 &#8211; Brooklyn ImmunoTherapeutics<a name="z_DV_C7"></a>, Inc. (NYSE
        American: BTX) ("Brooklyn")<a name="z_DV_M4"></a>, a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today
        announced the appointment of Kevin A. D&#8217;Amour, Ph.D. as its Chief Scientific Officer.</div>
      <div>&#160;</div>
      <div>Dr. D&#8217;Amour joins Brooklyn from ViaCyte, Inc., a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2
        diabetes, where he most recently served as Chief Scientific Officer.&#160; He holds more than 100 U.S. and international patents and has been widely published in nationally and internationally recognized peer review journals.&#160; Dr. D&#8217;Amour received his
        Ph.D. in Biology from the University of California, San Diego and his B.S. in Animal Science from the University of New Hampshire in Durham, New Hampshire.</div>
      <div>&#160;</div>
      <div>&#8220;Kevin&#8217;s significant experience in successful early- to clinical-stage development in the area of cell and gene-modified cell therapy makes him an excellent fit
        at Brooklyn, as we embark on what we believe will be pioneering work in multiple applications, many of which have no current treatments available,&#8221; said Howard J. Federoff, M.D., Ph.D., Brooklyn&#8217;s Chief Executive Officer and President. &#8220;We look
        forward to driving our work forward under Kevin&#8217;s leadership and we welcome him to Brooklyn.&#8221;</div>
      <div>&#160;</div>
      <div>Brooklyn&#8217;s exclusive access to the Factor Bioscience and Novellus technologies for mRNA-based gene-editing and cellular reprogramming, combined with the novel
        mRNA delivery system, provide a robust technology platform with a myriad of compelling therapeutic approaches. I look forward to helping successfully bring those approaches to the clinic and ultimately to patients,&#8221; added Dr. D&#8217;Amour.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About Brooklyn ImmunoTherapeutics</div>
      <div>&#160;</div>
      <div><a name="z_DV_M25"></a>Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent
        and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using highly innovative gene editing/cell therapy technology through the newly
        acquired license from Factor Bioscience and Novellus Therapeutics.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>Brooklyn&#8217;s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and
        neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.</div>
      <div>&#160;</div>
      <div>For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.</div>
      <div>&#160;</div>
      <div style="text-align: center;"><a name="z_DV_M28"></a><a name="z_DV_M29"></a><a name="z_DV_M30"></a><a name="z_DV_M34"></a>###</div>
      <div>&#160;</div>
      <div style="font-weight: bold;"><a name="z_DV_M35"></a><a name="z_DV_M36"></a><a name="z_DV_M37"></a><a name="z_DV_M38"></a>Investor Relations Contact:</div>
      <div>CORE IR</div>
      <div>516-222-2560</div>
      <div>investors@brooklynitx.com</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">Media Contact:</div>
      <div>CORE IR</div>
      <div>Jules Abraham</div>
      <div>julesa@coreir.com</div>
      <div>917-885-7378</div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !  /X# 2(  A$! Q$!_\0
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MN)-O5@F#M'IDXYKK/VE_^1^L_P#L'I_Z&]/_ &?=-2V\96-[>R,D]U;S?8X
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M1>?%&9$F & >.0<=?YUPGQ/\9W'Q*\0:=IV@V<YMHV*6T+#]Y-(W5R!T  _
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+445RG6%%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
